Dimension Therapeutics reports topline results from phase I/II program of lead AAV candidate Feb. 1, 2017 No Comments
FDA grants breakthrough therapy designation to uniQure's AMT-060 for hemophilia B Jan. 31, 2017 No Comments
Phase II results for crizanlizumab as prevention of pain crises in patients with sickle cell disease Jan. 10, 2017 No Comments
RSS